News

Categories

October 13, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

October 9, 2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

October 7, 2025

Zymeworks Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer Annual Meeting

September 26, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the European Respiratory Society Annual Congress

September 15, 2025

Zymeworks Announces Presentation at the European Respiratory Society (ERS) Congress 2025

September 2, 2025

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

August 19, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

August 11, 2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 7, 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

July 28, 2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 17, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 10, 2025

Zymeworks Wins Life Sciences BC 2025 Company of the Year Award